Cargando…
New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic
Glutamine is a non-essential amino acid that can be synthesized by cells. It plays a vital role in the growth and proliferation of mammalian cells cultured in vitro. In the process of tumor cell proliferation, glutamine not only contributes to protein synthesis but also serves as the primary nitroge...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745299/ https://www.ncbi.nlm.nih.gov/pubmed/36523985 http://dx.doi.org/10.3389/fonc.2022.1018642 |
_version_ | 1784849119958794240 |
---|---|
author | Yang, Xiaojing Li, Zhen Ren, Hanru Peng, Xue Fu, Jie |
author_facet | Yang, Xiaojing Li, Zhen Ren, Hanru Peng, Xue Fu, Jie |
author_sort | Yang, Xiaojing |
collection | PubMed |
description | Glutamine is a non-essential amino acid that can be synthesized by cells. It plays a vital role in the growth and proliferation of mammalian cells cultured in vitro. In the process of tumor cell proliferation, glutamine not only contributes to protein synthesis but also serves as the primary nitrogen donor for purine and pyrimidine synthesis. Studies have shown that glutamine-addicted tumor cells depend on glutamine for survival and reprogram glutamine utilization through the Krebs cycle. Potential therapeutic approaches for ovarian cancer including blocking the entry of glutamine into the tricarboxylic acid cycle in highly aggressive ovarian cancer cells or inhibiting glutamine synthesis in less aggressive ovarian cancer cells. Glutamine metabolism is associated with poor prognosis of ovarian cancer. Combining platinum-based chemotherapy with inhibition of glutamine metabolic pathways may be a new strategy for treating ovarian cancer, especially drug-resistant ovarian cancer. This article reviews the role of glutamine metabolism in the biological behaviors of ovarian cancer cells, such as proliferation, invasion, and drug resistance. Its potential use as a new target or biomarker for ovarian cancer diagnosis, treatment, and the prognosis is investigated. |
format | Online Article Text |
id | pubmed-9745299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97452992022-12-14 New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic Yang, Xiaojing Li, Zhen Ren, Hanru Peng, Xue Fu, Jie Front Oncol Oncology Glutamine is a non-essential amino acid that can be synthesized by cells. It plays a vital role in the growth and proliferation of mammalian cells cultured in vitro. In the process of tumor cell proliferation, glutamine not only contributes to protein synthesis but also serves as the primary nitrogen donor for purine and pyrimidine synthesis. Studies have shown that glutamine-addicted tumor cells depend on glutamine for survival and reprogram glutamine utilization through the Krebs cycle. Potential therapeutic approaches for ovarian cancer including blocking the entry of glutamine into the tricarboxylic acid cycle in highly aggressive ovarian cancer cells or inhibiting glutamine synthesis in less aggressive ovarian cancer cells. Glutamine metabolism is associated with poor prognosis of ovarian cancer. Combining platinum-based chemotherapy with inhibition of glutamine metabolic pathways may be a new strategy for treating ovarian cancer, especially drug-resistant ovarian cancer. This article reviews the role of glutamine metabolism in the biological behaviors of ovarian cancer cells, such as proliferation, invasion, and drug resistance. Its potential use as a new target or biomarker for ovarian cancer diagnosis, treatment, and the prognosis is investigated. Frontiers Media S.A. 2022-11-29 /pmc/articles/PMC9745299/ /pubmed/36523985 http://dx.doi.org/10.3389/fonc.2022.1018642 Text en Copyright © 2022 Yang, Li, Ren, Peng and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Xiaojing Li, Zhen Ren, Hanru Peng, Xue Fu, Jie New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title | New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title_full | New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title_fullStr | New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title_full_unstemmed | New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title_short | New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
title_sort | new progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745299/ https://www.ncbi.nlm.nih.gov/pubmed/36523985 http://dx.doi.org/10.3389/fonc.2022.1018642 |
work_keys_str_mv | AT yangxiaojing newprogressofglutaminemetabolismintheoccurrencedevelopmentandtreatmentofovariancancerfrommechanismtoclinic AT lizhen newprogressofglutaminemetabolismintheoccurrencedevelopmentandtreatmentofovariancancerfrommechanismtoclinic AT renhanru newprogressofglutaminemetabolismintheoccurrencedevelopmentandtreatmentofovariancancerfrommechanismtoclinic AT pengxue newprogressofglutaminemetabolismintheoccurrencedevelopmentandtreatmentofovariancancerfrommechanismtoclinic AT fujie newprogressofglutaminemetabolismintheoccurrencedevelopmentandtreatmentofovariancancerfrommechanismtoclinic |